Chris Whittaker is a managing director in Evercore’s healthcare strategic advisory business based in London. Having joined Evercore in 2019, he has worked extensively with clients across subsectors with a key focus on life sciences and associated pharma services.
Notable transactions include advising AstraZeneca on acquisition of Alexion, Sanofi on its acquisition of Principia Biopharma, F2G on its strategic collaboration with Shionogi, and Agenus on its licensing agreement with BMS. Mr Whittaker also has been involved in initial public offerings and follow-on equity offerings for biotech companies.
Previously, Mr. Whittaker spent 13 years at Rothschild & Co based in London, where advisory assignments included BTG on the $4.2 billion recommended cash offer from Boston Scientific; PellePharm on its $760 million development, merger and commercialization collaboration with LEO Pharma; and Concept Life Sciences Group on the sale to Spectris.
Mr. Whittaker holds an M.A. in natural sciences from Christ’s College, Cambridge University, U.K., and undertook post-graduate studies at the Laboratory of Molecular & Cellular Biology at University College London.